Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Instil Bio Inc TIL

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.


NDAQ:TIL - Post by User

Bullboard Posts
Post by thegoldfishon May 15, 2014 2:47pm
186 Views
Post# 22566465

Bitter bye-bye to this dog

Bitter bye-bye to this dogI've thrown in the towel on this change-the-name-of-the-company-every-week, change-the-business-model-as-often, keep-blowing-smoke piece of trash.

Fittingly, it even will cost me extra to dump it via Schwab's global trading desk (I'm American) due to the lack of a symbol for U.S. trading. I should know in a half hour -- ridiculous delay, I know -- whether some sucker (optimist) bought my offered shares.

Good luck to all who remain. Management has treated you (us) like dirt, being consistent only in dropping the ball and failing to deliver on varied promises. I just can't keep my dwindling money in some sort of black box, trust-us-it-will-work-out business. I trusted way too long. What's next for these chameleons? A foray into the hot marijuana sector?

This is one reason why the junior market is currently moribund. It's going to take a long time before investors become trusting, or stupid, enough to buy these story stocks.



Bullboard Posts